This afternoon we watched BioMarin Pharmaceutical drop -3.1% to a price of $52.49 per share. The Large-Cap Pharmaceutical company is now trading -41.26% below its average target price of $89.36. Analysts have set target prices ranging from $55.0 to $122.0 per share for BioMarin Pharmaceutical, and have given the stock an average rating of buy.
BioMarin Pharmaceutical has an average level of shares sold short, at 6.6% of its total share float. The stock's short ratio (also called days to cover) is 3.67. The company's insiders own 0.78% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 97.9% of BioMarin Pharmaceutical's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in BioMarin Pharmaceutical
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Blackrock Inc. | 11% | 22,046,050 | $1,157,283,150 |
| 2025-09-30 | Vanguard Group Inc | 10% | 18,582,585 | $975,472,364 |
| 2025-09-30 | Primecap Management Company | 8% | 15,229,287 | $799,444,673 |
| 2025-09-30 | Dodge & Cox Inc. | 8% | 14,686,801 | $770,967,467 |
| 2025-09-30 | State Street Corporation | 5% | 8,764,599 | $460,087,986 |
| 2025-09-30 | Viking Global Investors, L.P. | 4% | 8,322,179 | $436,863,634 |
| 2025-09-30 | AQR Capital Management, LLC | 3% | 5,932,109 | $311,399,538 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 3,542,120 | $185,939,694 |
| 2025-09-30 | Millennium Management Llc | 1% | 2,627,210 | $137,912,499 |
| 2025-09-30 | Capital Research Global Investors | 1% | 2,537,596 | $133,208,311 |
